Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Anxiety disorders are the most common mental health conditions in the United States, affecting an estimated 40 million adults. While SSRIs, SNRIs, and benzodiazepines help many patients, a substantial subset — perhaps 30% to 40% — do not achieve adequate relief with standard treatments. For patients with treatment-refractory generalized anxiety disorder (GAD), options have been limited. A 2017 dose-ranging study offered early evidence that ketamine may help.
Paul Glue and colleagues published a study in the Journal of Psychopharmacology in 2017 that examined the dose-related effects of subcutaneous ketamine on anxiety symptoms in patients with treatment-refractory anxiety disorders, including GAD and social anxiety disorder. This was an ascending-dose study in which 12 patients received single doses of ketamine at 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg on separate occasions, with washout periods between doses.
The study found a clear dose-response relationship. Higher doses of ketamine produced greater reductions in anxiety symptoms, as measured by the Fear Questionnaire and the Visual Analogue Scale for anxiety. At the two higher doses (0.5 and 1.0 mg/kg), the anxiolytic effects were significant and persisted for up to seven days in some patients. The onset of anxiety reduction was rapid — within hours — mirroring the time course seen in ketamine's antidepressant effects.
This was a small, open-label study without a placebo control, which limits the strength of the conclusions. However, the dose-response relationship is an important pharmacological signal: when higher doses produce greater effects in a systematic pattern, it suggests a genuine drug effect rather than placebo response. The study population was also clinically relevant — these were patients who had failed multiple prior anxiety treatments.
For clinicians treating anxiety disorders, the Glue et al. study is noteworthy because it is one of the few trials to examine ketamine specifically in an anxiety-disordered (rather than depressed) population. While many ketamine depression studies report secondary improvements in anxiety, those findings are confounded by the overlap between depressive and anxious symptoms. This study isolated anxiety as the primary target.
The glutamatergic mechanism behind ketamine's effects may be particularly relevant to anxiety. Anxiety disorders involve hyperactivation of the amygdala and disrupted connectivity between the prefrontal cortex and limbic structures. Preclinical evidence suggests that NMDA receptor modulation and BDNF-mediated neuroplasticity may help restore balance in these circuits. If larger controlled trials confirm these findings, ketamine could represent a new mechanistic approach to treatment-resistant anxiety.
It is essential to note that ketamine is not FDA-approved for the treatment of any anxiety disorder. The evidence is preliminary, and larger randomized controlled trials are needed.
If you have been living with generalized anxiety that has not responded to standard medications and therapy, the Glue et al. study suggests that ketamine may be worth discussing with your physician. The evidence is early-stage, but the dose-response relationship and rapid onset of effect are encouraging signals.
Many patients seeking ketamine therapy have both depression and anxiety. The existing evidence suggests that ketamine may address both symptom domains through its effects on glutamate signaling and neuroplasticity. If anxiety is your primary concern, it is important to work with a physician who can evaluate your specific situation and discuss whether ketamine is appropriate given the current evidence base.
A dose-ranging study in patients with treatment-refractory anxiety disorders found that ketamine produced dose-dependent reductions in anxiety symptoms, with effects evident within hours and persisting for up to a week. While larger controlled trials are needed, this early evidence suggests ketamine may offer a new pathway for patients who have not responded to conventional anxiety treatments.
Reference: Glue P, Medlicott NJ, Harland S, et al. "Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders." Journal of Psychopharmacology. 2017;31(10):1302-1305. PMID: 28944714
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
